384 related articles for article (PubMed ID: 24048106)
1. Psoriasiform reactions to anti-tumor necrosis factor α therapy.
Nguyen K; Vleugels RA; Velez NF; Merola JF; Qureshi AA
J Clin Rheumatol; 2013 Oct; 19(7):377-81. PubMed ID: 24048106
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
[TBL] [Abstract][Full Text] [Related]
6. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
7. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
[TBL] [Abstract][Full Text] [Related]
8. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.
Seneschal J; Milpied B; Vergier B; Lepreux S; Schaeverbeke T; Taïeb A
Br J Dermatol; 2009 Nov; 161(5):1081-8. PubMed ID: 19681863
[TBL] [Abstract][Full Text] [Related]
9. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
10. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
11. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
Lozeron P; Denier C; Lacroix C; Adams D
Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
13. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.
Ko JM; Gottlieb AB; Kerbleski JF
J Dermatolog Treat; 2009; 20(2):100-8. PubMed ID: 18923992
[TBL] [Abstract][Full Text] [Related]
14. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.
Osório F; Magro F; Lisboa C; Lopes S; Macedo G; Bettencourt H; Azevedo F; Magina S
Dermatology; 2012; 225(2):163-7. PubMed ID: 23052429
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
18. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
19. [Alopecia areata during anti-TNF alpha therapy: Nine cases].
Le Bidre E; Chaby G; Martin L; Perrussel M; Sassolas B; Sigal ML; Kaassis C; Lespessailles E; Nseir A; Estève E
Ann Dermatol Venereol; 2011; 138(4):285-93. PubMed ID: 21497255
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup.
Schmidt J; Kermani TA; Bacani AK; Crowson CS; Matteson EL; Warrington KJ
Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1079-83. PubMed ID: 22328491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
